Tivozanib Survival Data Go Wrong Way With One-Way Crossover Design
Executive Summary
Aveo’s decision to allow only patients on the pivotal trial’s comparator arm to cross over to subsequent targeted therapy was a design flaw that made it impossible to assess the true picture of tivozanib’s effect on overall survival, FDA advisory committee members said.